Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CFO James E. Fickenscher bought 5,200 shares of Zynerba Pharmaceuticals stock in a transaction that occurred on Friday, May 12th. The shares were acquired at an average cost of $19.82 per share, for a total transaction of $103,064.00. Following the acquisition, the chief financial officer now owns 12,200 shares in the company, valued at approximately $241,804. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) traded down 3.84% during midday trading on Friday, hitting $18.05. 382,240 shares of the stock traded hands. The firm’s 50-day moving average is $21.29 and its 200-day moving average is $18.42. Zynerba Pharmaceuticals Inc has a 52-week low of $6.31 and a 52-week high of $25.95. The company’s market cap is $238.51 million.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings results on Tuesday, May 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by $0.05. Analysts predict that Zynerba Pharmaceuticals Inc will post ($2.43) EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. J. Goldman & Co LP purchased a new position in Zynerba Pharmaceuticals during the fourth quarter worth $1,113,000. GSA Capital Partners LLP purchased a new position in Zynerba Pharmaceuticals during the fourth quarter worth $214,000. Perceptive Advisors LLC purchased a new position in Zynerba Pharmaceuticals during the fourth quarter worth $13,128,000. Putnam Investments LLC purchased a new position in Zynerba Pharmaceuticals during the fourth quarter worth $725,000. Finally, Rothschild Investment Corp IL boosted its position in Zynerba Pharmaceuticals by 95.0% in the first quarter. Rothschild Investment Corp IL now owns 45,620 shares of the company’s stock worth $917,000 after buying an additional 22,225 shares during the period. Institutional investors and hedge funds own 15.00% of the company’s stock.
A number of brokerages have issued reports on ZYNE. Canaccord Genuity set a $35.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 13th. Roth Capital set a $30.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price target on shares of Zynerba Pharmaceuticals in a report on Tuesday, May 9th. Oppenheimer Holdings Inc. set a $29.00 price target on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, April 1st. Finally, Zacks Investment Research lowered shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 29th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.44.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/zynerba-pharmaceuticals-inc-zyne-cfo-buys-103064-00-in-stock/1836562.html
Receive News & Ratings for Zynerba Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.